
Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors
Keywords: سورفانیب; HCC; hepatocellular carcinoma; RCC; renal cell carcinoma; GI50; concentration required to inhibit cell growth by 50%; EpFAs; epoxygenated fatty acids; t-CUPM; trans-4-{4-[3-(4-chloro-3-trifluoromethyl-phenyl)-ureido]-cyclohexyloxy}-pyridine-2-carboxylic a